Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated

Initial Statement of Beneficial Ownership

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Charles F. Wagner	Executive VP, COO & CFO Show All	Automatic Disposition (Automatic Disposition)	-14.0K	-0.005517%	-47.8%	15.3K	451.0 - 461.0	-6.4M	05 Dec 2025	03 Dec 2025 - 03 Dec 2025
Ourania Tatsis	Executive VP and Chief Regulatory & Quality Officer Show All	Automatic Disposition (Automatic Disposition)	-4.5K	-0.001773%	-14.8%	25.9K	450.0 - 450.0	-2.0M	05 Dec 2025	03 Dec 2025 - 03 Dec 2025
Jeffrey Marc Leiden	Executive Chairman Show All	Derivative Exercise and Sale (Derivative Exercise and Sale)	-63.8K	-0.025138%	—	24.5K	86.5 - 455.2	-23.1M	05 Dec 2025	03 Dec 2025 - 03 Dec 2025
Jeffrey Marc Leiden	Executive Chairman Show All	Derivative Exercise and Retained Stock (Derivative Exercise and Retained Stock)	1.0	—	0.0%	24.5K	91.1 - 91.1	91.0	05 Dec 2025	04 Dec 2025 - 04 Dec 2025
Jonathan Biller	Executive VP & Chief Legal Officer Show All	Automatic Disposition (Automatic Disposition)	-347.0	-0.000136%	-2.2%	15.3K	449.0 - 449.0	-155.8K	05 Dec 2025	03 Dec 2025 - 03 Dec 2025
Jeffrey Marc Leiden
Charles F. Wagner
Charles F. Wagner
Ourania Tatsis
Jonathan Biller
Lloyd A. Carney
Lloyd A. Carney
Edward Morrow Atkinson
Jeffrey Marc Leiden
Edward Morrow Atkinson
Jeffrey Marc Leiden
Jeffrey Marc Leiden
Suketu P. Upadhyay
Bruce I. Sachs
Jonathan Biller
Jonathan Biller
Jonathan Biller
Sangeeta N. Bhatia
Sangeeta N. Bhatia
Reshma Kewalramani
Bruce I. Sachs
Suketu P. Upadhyay
Bruce I. Sachs
Duncan J. McKechnie
Stuart A. Arbuckle